Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
June 08 2021 - 7:05AM
Business Wire
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced the appointment of Chris Freeman as the
company’s new Chief Commercial Officer for its oncology business,
effective June 8, 2021. Chris brings significant experience
successfully building and managing pharmaceutical and biotechnology
brands through all stages of commercialization, which will be
invaluable as the company’s oncology portfolio expands to cover
advanced and earlier stage cancers.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210608005443/en/
Chris Freeman (Photo: Business Wire)
“I am thrilled to welcome Chris Freeman as our new Chief
Commercial Officer. Chris’s broad experience leading blockbuster
products through commercialization will be essential as we continue
to develop and scale our portfolio of products for advanced and
early-stage cancers and effectively deploy precision oncology to
improve outcomes for patients,” said Helmy Eltoukhy, Guardant
Health CEO. “Chris’s leadership and business acumen will be vital
as we build the commercial capabilities needed to drive growth in
both existing and new market segments as we serve cancer patients
across all stages of the disease.”
“I am excited to join Guardant Health in their mission to
improve cancer care for all patients,” said Chris Freeman. “The
company has made great inroads in introducing cutting-edge new
products to improve outcomes in advanced and most recently
early-stage cancer, but there remains the challenge of accelerating
clinical adoption so that all patients can benefit from precision
oncology advancements. I am eager to work with the talented team at
Guardant Health to introduce and expand access to ground-breaking
new products as well as make sure that clinicians and the patients
they serve are aware of how our products can help improve cancer
care across the care continuum.”
Prior to joining Guardant Health, Chris worked for the last ten
years at Gilead Sciences, Inc. where he served most recently as
Vice President of their HIV Business Unit, leading the $13 billion
HIV treatment and prevention business. During the COVID-19
pandemic, Chris led the Emergency Use Authorization for Veklury
(remdesivir) to treat COVID-19. Chris previously worked at Elan
Pharmaceuticals where he was commercial lead for Elan’s Alzheimer's
pipeline products, and he spent six years at Genentech where he led
marketing for their oncology product, Rituxan, and Xolair for
patients suffering from asthma and severe allergies. Chris is a
member of the National Board of Directors for Dream Foundation, a
national dream-granting organization for terminally ill adults and
their families.
Chris served in the U.S. Army for five years, first enlisting as
a Lieutenant and was promoted to Captain before being honorably
discharged in 2001. Chris is a graduate of the United States
Military Academy at West Point.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
blood tests, vast data sets, and advanced analytics. The Guardant
Health oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes, and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched liquid biopsy-based Guardant360®,
Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer
patients, and Guardant Reveal™ test for early-stage cancer
patients. These tests fuel development of its LUNAR screening
program, which aims to address the needs of asymptomatic
individuals eligible for cancer screening.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210608005443/en/
Investor Contact: Carrie Mendivil
investors@guardanthealth.com
Media Contact: Anna Czene press@guardanthealth.com
Julie Johnson julie.johnson@uncappedcommunications.com
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Apr 2024 to May 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From May 2023 to May 2024